Recombinant novel coronavirus vaccine (adenovirus type 5 vector) (CanSinoBio)

重组新型冠状病毒疫苗（5型腺病毒载体）（康希诺生物）

Report date: 2023/11/01 10:57:44

Base Information

Drug NameRecombinant novel coronavirus vaccine (adenovirus type 5 vector) (CanSinoBio)
Drug Alias NameAd5-nCoV克威莎ConvideciaConvidecia Air
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Recombinant vector vaccine +[4] 
Mechanisms of ActionImmunostimulantsCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaCoronavirus Disease 2019 (COVID-19)
Original Approved Country/TerritoryMainland China
Original Approved Date2021/02/25
Country/TerritoryCanadaPakistanMexico +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTianjin Cansino Biotechnology IncChinese Academy Of Military Medical Sciences
China Registration ClassN/A

Develop Information

Active CompaniesNpo PetrovaxCanSino Biologics IncTianjin Cansino Biotechnology Inc
Inactive CompaniesInstitute Of Biotechnology, Academy Of Military Medical Sciences. Pla Of ChinaJiangsu Provincial Center For Disease Control And Prevention
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeJ07B
Related LinksN/A